Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Matched Targeted Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07802418
What this trial is testing

Molecularly Tailored Therapy in Advanced Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Herlev Hospital 1,200
Not applicableUnknownNCT05177666
What this trial is testing

A Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Who this might be right for
FeasibilityEffectivenessSafety+1 more
The University of Hong Kong-Shenzhen Hospital 120
Not applicableActive Not RecruitingNCT02670525
What this trial is testing

Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome

Who this might be right for
Recurrent, Refractory, or High Risk LeukemiasMatched Targeted Therapy
Dana-Farber Cancer Institute 338
Testing effectiveness (Phase 2)Active Not RecruitingNCT06360575
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 20
Testing effectiveness (Phase 2)Study completedNCT02795156
What this trial is testing

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Who this might be right for
Non-small Cell Lung CarcinomaUrothelial CarcinomaGastrointestinal Carcinoma, Non-colon+1 more
SCRI Development Innovations, LLC 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT06360588
What this trial is testing

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Who this might be right for
Malignant Solid Neoplasm
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Looking for participantsNCT07510828
What this trial is testing

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Who this might be right for
Advanced or Metastatic Solid Tumors
Beijing Biotech 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06308822
What this trial is testing

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439253
What this trial is testing

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439318
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385496
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06390839
What this trial is testing

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+1 more
National Cancer Institute (NCI) 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT05490771
What this trial is testing

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphatic System Neoplasm+3 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT06357975
What this trial is testing

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439188
What this trial is testing

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 35
Not applicableLooking for participantsNCT03452774
What this trial is testing

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Who this might be right for
Cancer, MetastaticCancerCancer of Pancreas+40 more
Massive Bio, Inc. 50,000
Testing effectiveness (Phase 2)Study completedNCT04173585
What this trial is testing

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

Who this might be right for
Acute Myeloid Leukemia
University Hospital Heidelberg 50
Testing effectiveness (Phase 2)Study completedNCT04439240
What this trial is testing

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 52
Testing effectiveness (Phase 2)Active Not RecruitingNCT06400225
What this trial is testing

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Next Page